Corcept Therapeutics Incorporated

NASDAQ:CORT

Biotechnology

Healthcare
$67.79 -2.34%

-$1.96 today

Market cap
$7.42B
Beta
0.50
P/E (TTM)
178.2
EPS (TTM)
$0.46
52W Low $28.66High $91.00

Volume 0.74M

Average 1.41M

CORT EBITDA Margin

EBITDA as a percentage of revenue.

Corcept Therapeutics IncorporatedNASDAQ: CORT

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin widens to 18.3%

EBITDA Margin was 18.3% in Q2 FY2026, up 1.7 pp from a year earlier. On a trailing-twelve-month basis it was 3.5%, down 14.4 pp year over year. Over 3 fiscal years it narrowed by 20.8 pp.

Context

  • EBITDA Margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 3 analysts of 27.8% for the fiscal year ending Dec 2026, up from 9.0% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
18.3%+45.0 pp QoQ
Last fiscal yearDec 2025
9.0%-15.1 pp YoY
LTMJun 2026
3.5%-14.4 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+1.7 pp+26.7 pp+25.0 pp
1 year-15.1 pp+18.8 pp+34.0 pp
3 years-20.8 pp+48.7 pp+69.5 pp
5 years+42.7 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
9.0%
Year-over-year change
-15.1pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How CORT compares with its peers on the latest reported figures

CORT Competitors
EBITDA Margin for CORT and competitors
Company Period LTM level YoY 3-year change
CORTCorcept Therapeutics IncorporatedLTM Jun 20263.5% -14.4 pp-20.8 pp
MBXMBX Biosciences, Inc. Common StockFY2025— ——
SPRBSpruce Biosciences, Inc.FY2025— ——
Peer median (excluding CORT) ———

Competitors are the stored peer set for CORT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue365.98M401.86M482.38M675.04M761.41M
Cost of Revenue5.28M5.39M6.48M10.88M12.98M
Gross Profit360.7M396.47M475.89M664.16M748.43M
Gross Margin98.6%98.7%98.7%98.4%98.3%
Research & Development113.86M130.99M184.35M246.89M254.91M
Selling, General & Admin122.36M152.85M184.26M280.32M448.73M
Operating Expenses236.22M283.84M368.61M527.21M703.63M
Depreciation & Amortization3.07M3.45M2.36M1.34M1.89M
EBITDA127.95M119.64M126.92M162.83M68.35M
EBITDA Margin35.0%29.8%26.3%24.1%9.0%
Operating Income124.48M112.63M107.28M136.95M44.8M
Operating Margin34.0%28.0%22.2%20.3%5.9%
Interest Income529K3.56M17.28M24.54M21.67M
Interest Expense00000
Other Income / Expenses529K3.56M17.28M24.54M21.67M
Income Before Tax125.01M116.19M124.56M161.49M66.46M
Pre-Tax Margin34.2%28.9%25.8%23.9%8.7%
Income Tax Expense12.49M14.77M18.42M20.28M(33.19M)
Net Income112.51M101.42M106.14M139.73M99.65M
Net Margin30.7%25.2%22.0%20.7%13.1%
EPS (Basic)0.970.951.021.350.95
EPS (Diluted)0.890.870.941.230.82
Weighted Avg Shares115.65M106.79M103.56M103.23M103.86M
Weighted Avg Shares (Diluted)125.96M115.97M111.74M113.48M119.99M

Corcept Therapeutics Incorporated

NASDAQ:CORT

Intrinsic Alpha fair value

Locked

Current Price

$67.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.